|
|
|
|
|
TOKYO, Sept 14, 2023 - (JCN Newswire) - NEC Corporation (TSE: 6701) has been selected to participate in a vaccine/new modality research and development project beginning in FY2023. NEC was selected following its submission of a research project titled "Development of universal vaccine design technology using computational science" in response to a public call for proposals by the Strategic Center of Biomedical Advanced Vaccine Research and Development for Preparedness and Response (SCARDA), which operates under the Japan Agency for Medical Research and Development (AMED).
During this research project, NEC will utilize cutting-edge AI technologies in order to identify immunogenic regions that are effective against a wide range of influenza virus strains and to design a universal vaccine.
Background
Research on universal vaccines that are broadly protective against mutating viruses are being conducted around the world in preparation for future pandemics. However, it is likely to take a considerable amount of time for universal vaccines to be put to practical use. As such, expectations are high for the utilization of AI and other computational science approaches to shorten the vaccine development period and reduce associated costs.
Specifically, in Japan, the "Strategy for Strengthening Vaccine Development and Production Systems" was formulated in June 2021 as part of a long-term national strategy to develop and produce vaccines domestically. Later, in March 2022, SCARDA was established within AMED for the purpose of strategically funding research to bolster R&D and production systems for vaccines.
With the vision of using in-house AI technology for designing universal vaccines, NEC submitted a proposal in response to SCARDA's public appeal and was selected for the program.
NEC Research Overview
In this research project, a universal vaccine will be designed for influenza using a proprietary computer analysis technology based on several state-of-the-art AI technologies. Specifically, the genomic and genetic information of influenza viruses will be analyzed to search for and identify immunogenic regions, and verification tests will be conducted. NEC will then aim to design a vaccine based on these results within a year of the project initiation and to obtain a non-clinical PoC in the near future.
This research and development will be carried out in collaboration with specially appointed professor Keiko Udaka of Kochi University.
Future Plans
This research will move forward using cutting-edge AI and computational science to identify protein regions that are effective for vaccine designs. Moreover, NEC will utilize these research results to develop and put to practical use universal vaccines in collaboration with other partners having modality in order to effectively deliver benefits to patients.
"We are pleased that our proposal has been selected by SCARDA for the development of universal vaccine design technology through industry-government-academia collaboration. Amid expectations for the early development of vaccines, computational science, including AI technologies, is extremely important and can drive meaningful advances within the pharmaceutical industry. Going forward, NEC will continue contributing to global health and the provision of better vaccines by utilizing cutting-edge technologies," said Masamitsu Kitase, Corporate Senior VP and Head of the Healthcare and Life Science Division at NEC Corporation.
"Having worked together with NEC for many years on the development of a peptide immunotherapy for malignant tumors, I am truly looking forward to partnering with the company on the development of a universal vaccine for the influenza virus through this SCARDA program," said Keiko Udaka, M.D., Ph.D., specially appointed professor, Department of Immunology, School of Medicine, Kochi University. "I anticipate that AI and ICT will contribute to not only better vaccine development but also preemptive measures aimed at containing pandemics."
About NEC Corporation
NEC Corporation has established itself as a leader in the integration of IT and network technologies while promoting the brand statement of "Orchestrating a brighter world." NEC enables businesses and communities to adapt to rapid changes taking place in both society and the market as it provides for the social values of safety, security, fairness and efficiency to promote a more sustainable world where everyone has the chance to reach their full potential. For more information, visit NEC at www.nec.com.
Topic: Press release summary
Source: NEC Corporation
Sectors: Healthcare & Pharm
http://www.acnnewswire.com
From the Asia Corporate News Network
Copyright © 2025 ACN Newswire. All rights reserved. A division of Asia Corporate News Network.
|
|
|
|
|
|
|
| NEC Corporation |
| Feb 21, 2025 13:39 HKT/SGT |
|
NEC Innovation Challenge awards Canada's Prevu3D Inc. with the NEC Award and NOFF Award |
| Feb 21, 2025 11:00 HKT/SGT |
|
NEC Develops Near Real-time RIC for High Performance 5G vRAN |
| Feb 19, 2025 19:16 HKT/SGT |
|
NEC X & Carbide Ventures Partner To Rapidly Accelerate Early-Stage Startups |
| Feb 19, 2025 08:08 HKT/SGT |
|
NEC Orchestrating Future Fund invests in Aetion, a U.S.-based provider of healthcare analytics platforms |
| Feb 10, 2025 14:05 HKT/SGT |
|
NEC Solution Modernizes Network Infrastructure Construction Work |
| Jan 29, 2025 09:08 HKT/SGT |
|
NEC combines video analysis technology with generative AI to generate advice for improving work quality |
| Jan 27, 2025 11:01 HKT/SGT |
|
hootfolio, Inc., a Provider of Causal Analysis Technology, Launches Business Development |
| Jan 24, 2025 08:19 HKT/SGT |
|
World's First Successful Transmission of Huge Volume Mission Data Using 1.5 micron Optical Inter-Satellite Communication |
| Jan 17, 2025 11:47 HKT/SGT |
|
NEC Listed on the World Index and Asia Pacific Index of Dow Jones Sustainability Indices (DJSI) |
| Jan 10, 2025 10:37 HKT/SGT |
|
NEC and Biomy Partner to Develop and Expand AI-Based Analytical Platforms in the Digital Pathology Field |
| More news >> |
 |
|
|
|
